Potential effects of attention deficit hyperactivity disorder medication on body height and body weight in a longitudinal pediatric cohort study, the LIFE Child study.

Abstract

Purpose: To investigate the potential impact of drugs for the treatment of attention deficit hyperactivity disorder (ADHD) on body weight and height in children and adolescents from the LIFE ('Leipzig Research Centre for Civilization Diseases', Leipzig, Germany) Child cohort. Methods: We included 2,115 participants aged ≥6 to <18.25 years who attended the LIFE study center between 2011 and 2020 in our analysis, of whom 48 used ADHD drugs. Anthropometric and medication data from baseline to the third follow-up visit were available for 659 participants. Body height and body weight measurements were subsequently converted to z-scores. A repeated measures analysis of variance (ANOVA) was performed on the z-scores of both ADHD drug users and non-users to determine potential trends in body weight and body height from baseline to the 3 rd annual follow-up. Results: At the last visit with ADHD drug use of the 48 ADHD drug users, 40% (19/48) of the children and adolescents were below the 25 th reference percentile for weight. Z-scores for body height declined from baseline to the 3rd annual follow-up in individuals who used ADHD drugs (n=10; Differencemeans =-0.310; p=0.002) compared to non-users (n=649; Differencemeans =0.102; p<0.001). Body weight also decreased from baseline to 3rd follow-up in the ADHD drug group (n=10; Differencemeans =-0.473; p<0.001) compared to the non-user group (n=649; Differencemeans =0.015; p=0.161). Conclusion: We observed a potential tendency towards lower Z-scores for body height and body weight in individuals taking ADHD medication for an extended period compared to the corresponding age- and sex-matched populations.